Vanguard Global Advisers’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.2K Sell
18,036
-17,647
-49% -$33.7K ﹤0.01% 3225
2026
Q2
$71K Sell
35,683
-137,481
-79% -$198K ﹤0.01% 2942
2026
Q1
$220K Buy
+173,164
New +$326K ﹤0.01% 2400

Other funds holding HCAT

Vanguard Global Advisers's HCAT Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Health Catalyst (HCAT) stake by 49% in Q3 2026, selling an estimated $33.7K and leaving 18,036 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3225.

Vanguard Global Advisers first reported a position in HCAT in Q1 2026 and has held it in 3 quarters since. The position peaked at $220K in Q1 2026. 109 funds tracked by Wall St. Rank hold HCAT as of Q3 2026.

  • Vanguard Global Advisers held 18,036 shares of Health Catalyst worth $31.2K as of Q3 2026.
  • Vanguard Global Advisers sold 17,647 Health Catalyst shares in Q3 2026, an estimated $33.7K.
  • Health Catalyst made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3225 holding.
  • Vanguard Global Advisers first reported a position in Health Catalyst in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Health Catalyst position peaked at $220K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.